Introduction {#S1}
============

The lymphatic system plays pivotal roles in fluid balance, immune cell trafficking and lipid uptake ([@B131]; [@B27]; [@B81]), and lack or malfunction of lymphatic vessels leads to edema, disturbed immune responses and lipid malabsorption ([@B2]; [@B179]; [@B49]). The lymphatic vasculature is present in most organs, and consists of a complex branched network of capillaries (also called initial lymphatics), collecting vessels and lymph nodes. The blind-ended initial lymphatics are lined by a single layer of oak leaf-shaped endothelial cells, which are characterized by a sparse and highly perforated basement membrane, numerous anchoring filaments and lack of perivascular cell coverage ([@B65]; [@B132]; [@B167]; [@B148]). Fluids, macromolecules and immune cells that extravasate from blood capillaries are drained from the interstitium by the initial lymphatics. The absorbed fluid, known as lymph, flows towards collecting lymphatics, which are characterized by an intact basement membrane and are covered with smooth muscle cells. The collecting lymphatic vessels contain intraluminal valves to prevent the backflow of lymph, which is transported through progressively larger collecting vessels and lymph nodes, and eventually returns back to the blood circulation via lymphatic connections to major veins ([@B167]; [@B148]; [@B131]). Of note, the lymphatic system has been known since the mid-1660s to transport dietary lipids from the intestine to the blood circulation ([@B163]). Dietary fats are absorbed by intestinal enterocytes and assembled into triglyceride-enriched particles called chylomicrons. Thereafter, chylomicrons are taken up by initial intestinal lymphatics called lacteals and transported into the blood circulation via the lymphatic system ([@B135]; [@B11]; [@B131]; [@B27]).

Blood and lymphatic vessels are both lined with endothelial cells, which are connected by cell-cell junctions. Blood endothelial cell (BEC) junctions include adherens junctions expressing VE-cadherin, tight junctions expressing claudins and gap junctions characterized by connexin expression. BEC junctions are involved in a range of blood vascular processes, such as vasculogenesis, angiogenesis, vessel leak and leukocyte extravasation ([@B35]; [@B117]; [@B125]; [@B165]). LEC junctions, on the other hand, have unique structural characteristics reflecting the specific demands of the lymphatic vasculature. In lymphatic capillaries, discontinuous button-like junctions (buttons) ([Figure 1](#F1){ref-type="fig"}) endow these vessels with high permeability to allow the entry of interstitial fluid, macromolecules, lipids and immune cells, while collecting lymphatics have continuous zipper-like junctions (zippers) that strengthen the vascular barrier to allow lymph transport. Buttons and zippers are named based on their distinct morphology to distinguish focal sites of intercellular adhesions (buttons) in lymphatic capillaries, and mature junctions (zippers) in lymphatic collectors that are also present between endothelial cells of other blood vessels ([@B6]).

![Schematic of morphology, localization and protein components of LEC junctions. LECs lining initial and collecting lymphatics develop different cell-cell junctions to execute uptake and transport of lymph, respectively. The specialized discontinuous buttons in initial lymphatics serve as anchoring sites at the sides of interdigitated flaps of adjacent oak leaf-shaped LECs, and the loosely apposed border regions between buttons are entry sites for fluids, chylomicrons and immune cells. The endothelium of collecting vessels has continuous zippers that prevent vascular leak and allow transport of lymph, a process that is aided by smooth muscle cell coating and intraluminal valves. Adherens junction- and tight junction-associated proteins are enriched in both buttons and zippers. In mature initial lymphatics, most PECAM-1 and LYVE-1 are distributed at the tips of flaps between buttons. LEC, lymphatic endothelial cell.](fphys-11-00509-g001){#F1}

An increasing number of studies have now shown that lymphatic drainage requires properly organized LEC junctions that are dynamically remodeled; yet, the molecular basis of LEC junction remodeling in development and disease is at an early stage of investigation. Here, we discuss the current state-of-the-art on the molecular organization of LEC junctions in physiological and pathological contexts.

General Histology of LEC Junctions {#S2}
==================================

The oak leaf-shaped LECs of initial lymphatics have overlapping flaps that have long been recognized to be sites for the intercellular entry of fluids ([@B20]; [@B175]; [@B146]). A transcellular fluid transport mechanism has been also reported ([@B105]; [@B173]; [@B195]). When interstitial pressure increases due to local fluid accumulation and periodic tissue stress, the filaments that anchor LECs to the extracellular matrix pull on the flaps and open them, and the pressure gradients drive fluids and solutes to flow into initial lymphatics through the openings ([@B20]; [@B99]; [@B164]; [@B14]). The overlapping flaps are believed to serve as primary microvalves between LECs to prevent backflow of fluids from the lymphatic lumen into the interstitial space ([@B145], [@B146]; [@B175]; [@B14]). However, how initial lymphatics maintain their integrity while taking up fluids has been a mystery. Initial electron microscopy studies revealed that lymphatic capillaries in the ears of mice and guinea pigs possess open intercellular junctions that drained colloidal carbon, and described the existence of attachment plaques between membranes of adjacent LECs, with characteristic structural features of adherens junctions (zonula adherens) and tight junctions (zonula occludens) ([@B101]; [@B100]). A number of studies using gene profiling and cell biology approaches have also identified major junctional molecules expressed in primary and cultured LECs ([@B133]; [@B75]; [@B84]; [@B153]; [@B3]; [@B88]). The *in vivo* organization of LEC junctions, however, was unknown until high-resolution confocal microscopy studies identified discontinuous buttons in the endothelium of initial lymphatics and continuous zippers in collecting lymphatics ([@B6]; [@B34]; [@B193]).

Buttons are discontinuous junctions at the sides of interdigitated membrane flaps of neighboring endothelial cells of initial lymphatics. They are enriched with adherens junction- and tight junction-associated proteins and establish anchorage points for adjoining LECs, with an orientation parallel to the cell borders. Between buttons, the flap tips overlap loosely, thereby enabling unimpeded drainage into initial lymphatics driven by interstitial-to-intraluminal pressure gradients ([@B6]). This unique button structural organization allows for fluid entry via the tips of the LEC flaps, without the need for LEC junction dissolution, thus maintaining vessel integrity. Current evidence also supports that immune cell transmigration into initial lymphatics relies on the same button-flap structures ([@B132]; [@B83]), although this process is actively controlled by lymphatic endothelial chemokines and their corresponding receptors on leukocytes ([@B81]). Similar specialized buttons are observed in the initial lymphatics of many body tissues, including the trachea, dermis, diaphragm, bladder and small intestine ([@B6]; [@B34]; [@B193]; [@B10]; [@B70]; [@B198]).

It should be noted that discontinuous junctions can also occur in BECs, in response to growth factors and inflammatory mediators. However, these hyperpermeable junctions are structurally and functionally different from the buttons of initial lymphatics ([@B35]; [@B172]). Interestingly, airway epithelium can also form intercellular openings for plasma and leukocytes to traverse from the tissue into the lumen without disrupting the integrity of the epithelial lining ([@B47]; [@B56]).

The larger collecting lymphatic vessels are specialized for lymph transport, thus leakage should be restricted in those structures. The endothelial cells lining collecting lymphatics therefore have continuous junctions (zippers) without openings at the borders of adjacent LECs, which are similar in appearance to those seen in the endothelium of blood vessels ([@B6]). This feature, together with the continuous basement membrane of the LECs, endows collecting lymphatic vessels with low permeability that limits lymph leakage. In addition, LECs lining lymphatic valves appear to be joined by zippers as well ([@B182]).

Junctional Proteins in Lymphatics {#S3}
=================================

Despite the striking differences in their morphology, buttons and zippers are composed of the same junctional proteins, including the adherens junction components VE-cadherin, β-catenin and p120-catenin, the tight junction components occludin, claudin-5 and ZO-1, and tight junction-associated JAM-A and ESAM ([@B6]; [@B34]; [@B193]). These proteins are also expressed by BECs, where they participate in adherens and tight junction complexes at cell-cell contacts. LECs seem to organize these proteins into adherens and tight junction complexes at junctional points as well, as suggested by the ultrastructure of adherens junction and tight junction in electron microscopic images of lymphatic capillaries ([@B101]; [@B100]). In mature initial lymphatics, PECAM-1 and LYVE-1 are concentrated at the tips of LEC flaps and are spatially segregated from VE-cadherin-containing buttons at LEC borders ([@B6]; [@B193]). Some connexins, which are components of gap junctions, are also expressed in lymphatics ([@B89]; [@B115], [@B114]; [@B64]; [@B119], [@B118]; [@B21]). The expression pattern and function of these junctional proteins in the lymphatic vasculature are discussed below. Highlighted in particular are *in vivo* results documented by recent knockout mouse studies ([Table 1](#T1){ref-type="table"}).

###### 

Lymphatic vascular phenotypes after genetic deletion of junctional proteins.

  Genes                                 Mouse models                            Phenotypes
  ------------------------------------- --------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Adherens junction proteins**                                                
  VE-cadherin (Cdh5)                    *Cdh5^--/--^*                           Lethality at ∼E9.5−E10.5 due to undeveloped vascular structures ([@B18]; [@B68])
                                        *Cdh5^f/f^;Tie2Cre*                     Lethality at ∼E10.5 due to undeveloped vascular structures ([@B190])
                                        *Cdh5^f/f^;Lyve-1Cre*                   Lethality at ∼E10.5 probably due to defects in cardiovascular development ([@B190])
                                        *Cdh5^f/f^;Prox1CreER^T2^*              [Deletion at E10.5/E11.5/E12.5]{.ul}: severe edema and lymphatic hyperplasia at E14.5, and lethality at E14.5−E18.5. [Deletion at P2/P4 and analysis at 6 week]{.ul}: hyperplasic and fragmentized mesenteric lymphatics and lacteals, deteriorated lymphatic valves, mildly dilated dermal initial lymphatics with button junctions maintained, unregulated expression of tight junction proteins. [Adult deletion]{.ul}: hyperplasia and disintegration of mesenteric lymphatics and lacteals, lymphatic valve deterioration, unaltered structure of dermal initial lymphatics ([@B70])
                                        *Cdh5^f/f^;Prox1CreER^T2^;Prox1-GFP*    [Deletion at E10.5:]{.ul} edema and loss of lymphovenous valve formation at E16.5. [Deletion at E14.5:]{.ul} loss of lymphatic valve formation at E18.5. [Deletion at P1/P3 and analysis at P14:]{.ul} chylous ascites, regression of lymphatic valves ([@B190])
  β-catenin (Ctnnb1)                    *Ctnnb1^f/f^;Lyve-1Cre*                 Severe edema; Dilated lymphatic vessels with reduced sprouting capacity; Loss or impaired lymphovenous valve and lymphatic valve formation; Lethality before birth ([@B24])
  **Tight junction proteins**                                                   
  Claudin-5                             *Claudin-5^--/--^*                      Size-selective impairment of blood-brain barrier; Lethality within 10 h of birth; Lymphatic vascular phenotypes were not reported ([@B124])
                                        *Claudin-5^+/--^*                       Dilated and leaky lymphatic vessels and exacerbated edema and inflammation following ultraviolet B exposure ([@B112])
  JAM-A                                 *JAM-A^--/--^*                          Differentially altered leukocyte trafficking ([@B22], [@B23]; [@B187])
                                        *JAM-A^f/f^;Tie2Cre*                    Unaltered dendritic cell migration across lymphatic endothelium ([@B22])
  **Other junction-related proteins**                                           
  PECAM-1                               *Pecam1^--/--^*                         Partially dilated and mis-branched mesenteric lymphatics and abnormal lymphatic valve formation; Unaltered leukocyte *trans*-lymphatic migration ([@B6]; [@B182])
                                        *Pecam1^--/--^;Syndecan4^--/--^*        Increased mural cell coverage and more severe lymphatic abnormalities than *Pecam1^--/--^* single mutants, which cause blood-filled lymphatic and partial lethality before birth ([@B182])
  LYVE-1                                *Lyve-1^--/--^*                         Delayed lymphatic trafficking of dendritic cells; Unaffected lymphatic development and drainage function ([@B61]; [@B108]; [@B171]; [@B180])
  Connexins                             *Connexin37^--/--^*                     Lymphatic reflux; Enlargement of the jugular lymph sac; Defective lymphovenous valve and lymphatic valve formation; Unaffected lymphatic contractile capacity ([@B89]; [@B139], [@B140]; [@B64]; [@B119]; [@B21])
                                        *Connexin43^--/--^*                     No mesenteric lymphatic valves; Abnormally patterned thoracic duct; Perinatal lethality due to heart defects ([@B89]; [@B119])
                                        *Connexin43^f/f^;Lyve-1Cre*             Often sudden lethal chylothorax; Impaired lymphatic valve formation; Leaky or disrupted thoracic duct; Increased lymphatic capillary branching; Unaltered lymphatic contractile capacity ([@B118]; [@B21])
                                        *Connexin47^--/--^*                     Normal lymphatic development and function ([@B119]; [@B114]; [@B21])
                                        *Connexin37^--/--^;Connexin43^--/--^*   Severe lymphedema; Blood-filled lymphatics; Abnormal thoracic duct development; Dilated jugular lymph sac and dermal lymphatics; Perinatal lethality ([@B89])
                                        *Connexin37^--/--^;Connexin43^+/--^*    Lymphatic reflux and life-threatening chylothorax ([@B89])
                                        *Connexin43^--/--^;Connexin47^--/--^*   Mild edema; Loss of lymphovenous valve and mesenteric lymphatic valve formation; Lethality around birth ([@B119])
                                        *Connexin45^f/f^;NestinCre*             Impaired entrainment of spontaneous lymphatic contraction ([@B21])
                                        *Connexin45^f/f^;SmmhcER^T2^*           Reduced lymphatic contraction capacity 6--11 days after gene deletion at adult age ([@B21])
                                        *Connexin26^f/f^;Keratin5Cre*           Lymphedema; Dilated vessel diameters and reduced networking in dermal lymphatics; Lethality at E16.5−E18.5 ([@B40])

Adherens Junction Proteins {#S3.SS1}
--------------------------

In blood endothelial adherens junctions, VE-cadherin mediates adhesion through homophilic interactions *in trans* and associations with an intracellular protein network including α-, β-, and γ- and p120-catenin *in cis*. The intracellular proteins β- and p120-catenin stabilize endothelial adhesion by linking VE-cadherin to the actin cytoskeleton ([@B35]; [@B44]; [@B165]). In the lymphatic endothelium on the other hand, VE-cadherin is present at all junction types, and its distribution is particularly enriched in buttons ([@B6]; [@B34]; [@B193]). β- and p120-catenin colocalize with VE-cadherin at both buttons and zippers between LECs ([@B193]), but how adherens junction complexes are organized at these junctions is unclear. In BECs, VE-cadherin phosphorylation, internalization and degradation in response to differential vascular cues regulate the assembly and stability of adherens junctions and vascular permeability ([@B34]; [@B127]; [@B29]). Whether these mechanisms are responsible for button and zipper junction organization in LECs remains to be further investigated.

Constitutive loss of VE-cadherin causes embryonic lethality at approximately embryonic day (E) 9.5−E10.5, before the development of lymphatic vasculature ([@B18]; [@B68]; [@B190]). Studies using tamoxifen-inducible genetic models have revealed that prenatal LEC-specific deletion of VE-cadherin leads to an aberrant primitive lymphatic plexus, loss of lymphatic valves, edema and fetal death ([@B70]; [@B190]). Similarly, mice with constitutive deletion of β-catenin in LECs exhibit significantly dilated lymphatic sacs, lack of lymphatic valves, severe edema and prenatal lethality ([@B24]). Postnatal or adult deletion of VE-cadherin also impairs the integrity of lacteals and mesenteric lymphatic collectors and the maintenance of lymphatic valves, whereas mature adult dermal lymphatics are resistant to VE-cadherin loss ([@B70]; [@B190]). Interestingly, VE-cadherin loss causes chylous ascites, possibly resulting from lymph leakage from mesenteric collecting vessels due to endothelial barrier dysfunction, as well as valve deterioration, which enables retrograde flow of lymph from larger collecting vessels into lymphatic tributaries where chyle is prone to leak ([@B123]). Growing *in vivo* evidence ([@B70]; [@B190]) supports that the lymphatic vasculature uses VE-cadherin as a mechanotransducer at junctional sites, similarly to the blood vasculature ([@B176]; [@B30]). Due to the high flow shear at valve sinuses, lymphatic valves may be particularly susceptible to defective cell-cell adhesion and mechanotransduction; this could explain why lymphatic valves deteriorate upon VE-cadherin deletion. At the molecular level, VE-cadherin regulates a number of signaling pathways that are crucial for LEC junction maturation, proliferation and mechanotransduction, including the β-catenin, VEGFR/AKT, YAP/TAZ, PROX1 and FOXC2 pathways ([@B140]; [@B70]; [@B190]). Taken together, these results suggest that VE-cadherin, in addition to mediating cell-cell adhesion, acts also as a membrane signaling hub to transfer intracellular signals in LECs.

Tight Junction Proteins {#S3.SS2}
-----------------------

Tight junctions join endothelial cells of all blood vessels and are most abundant in cerebrovascular endothelial cells. In brain microvessels, multiple interconnected strands of tight junction structures are present at the apical borders of joining endothelial cells, thereby limiting permeability of the blood-brain barrier ([@B158]; [@B35]; [@B69]). As mentioned previously, in LECs both buttons and zippers express the endothelial tight junction constituents claudin-5, occludin and ZO-1, as well as the associated proteins JAM-A and ESAM. Although the distribution of those proteins overlaps with VE-cadherin ([@B6]; [@B34]; [@B193]), VE-cadherin deletion or functional inactivation does not alter the distribution of tight junction proteins in buttons and zippers, indicating that tight junction organization is independent of adherens junctions in lymphatic vessels ([@B6]; [@B70]). As previously shown in epithelial cells and BECs, tight junctions usually occupy the apical end of the junctional clefts, while adherens junctions are more basal ([@B121]; [@B34]). It is possible that this organization is also maintained at buttons and zippers in LECs. The expression of tight junction proteins such as claudin-5, ZO-1 and JAM-A is upregulated in VE-cadherin-deleted LECs, which may represent a compensatory response following the loss of VE-cadherin ([@B70]). Claudin-5 is a key constituent of endothelial tight junctions. *Claudin-5^--/--^* mice die within 10 h of birth, and their blood-brain barrier function is impaired against small molecules ([@B124]). Importantly, *Claudin-5^+/--^* mice show dilated and leaky lymphatics after ultraviolet B irradiation ([@B112]). While the exact roles of claudin-5 in different lymphatics have yet to be elucidated, these results indicate that a claudin-5-dependent barrier may be required for the maintenance of collective lymphatic vessel integrity. Finally, the expression of the tight junction-associated protein JAM-A in LECs does not play a role in lymphatic regulation of leukocyte trafficking ([@B22]), despite the fact that JAM-A expressed in BECs and certain leukocyte populations, such as dendritic cells, neutrophils and monocytes, has been shown to facilitate leukocyte transmigration ([@B22]; [@B187]; [@B23]; [@B147]). Taken together, our understanding of lymphatic tight junctions is still limited, and the dynamics of tight junction proteins in lymphatic development and function have yet to be elucidated.

PECAM-1 {#S3.SS3}
-------

The endothelial adhesion molecule PECAM-1 is expressed at a high density at the cell borders of all endothelial cells in the blood and lymphatic vasculature ([@B143]; [@B171]). In blood vessels, PECAM-1 acts as a regulator of endothelial cell junction integrity and mechanotransduction and plays an important role in leukocyte transendothelial migration ([@B28]; [@B134]; [@B25]). PECAM-1 distribution in LECs shows partial overlap with VE-cadherin in buttons and zippers, but it does not appear to regulate VE-cadherin localization, or the junctional integrity of buttons ([@B6]). In lymphatic capillaries, PECAM-1 lines mostly the tips of flaps that constitute channels of leukocyte entry ([@B6]). To this end, LECs express the chemokine CCL21, which is sensed by the leukocyte receptor CCR7 and provides migration cues for skin dendritic cells toward initial lymphatics ([@B57]; [@B141]). *In vitro*, a PECAM-1-blocking antibody inhibits dendritic cell migration across TNFα-inflamed LEC monolayers and skin explants, suggesting that PECAM-1 may regulate leukocyte migration into lymphatics ([@B171]). However, such a role is not supported by *in vivo* evidence, as *Pecam1-null* mice have normal leukocyte trafficking into afferent lymphatics ([@B6]). Finally it has been suggested that PECAM-1 may act as a regulator of lymphatic valve formation and a flow sensor in LECs ([@B182]).

LYVE-1 {#S3.SS4}
------

Lymphatic vessel endothelial receptor 1 is the major receptor for the ubiquitous glycosaminoglycan hyaluronan in the lymphatic vasculature ([@B7]) with a preferential distribution in initial lymphatics over large collective vessels ([@B6]), although it is also expressed in some macrophage and BEC populations ([@B116]; [@B26]; [@B188]; [@B67]; [@B104]). *Lyve-1-null* mice exhibit normal lymphatic development and tissue fluid drainage, suggesting that LYVE-1 is not required for these lymphatic functions ([@B61]; [@B108]). However a role for LYVE-1 as a lymphatic-specific receptor for leukocyte trafficking has been recently demonstrated ([@B98]; [@B83]; [@B180]; [@B80]). Dendritic cells express hyaluronan on their surface, which during *trans*-lymphatic migration binds to LYVE-1-lined ring-like openings at LEC borders ([@B83]). This interaction enables dendritic cell docking to the basolateral surface of initial lymphatics, and the openings allow for dendritic cell entry ([@B83]; [@B80]). In addition to dendritic cells, macrophages may also utilize the same LYVE-1-hyaluronan axis for transport through inflamed lymphatic endothelium ([@B98]; [@B180]). LYVE-1 internalization ([@B85]) or shedding ([@B186]) from the lymphatic endothelium allows for the subsequent release of leukocytes into the lymphatic vessel lumen. These findings illustrate a role for the LYVE-1-hyaluronan complex in leukocyte trafficking through initial lymphatic openings defined by button junctions. Notably, previous studies have revealed that in inflamed tissues, dendritic cell trafficking into lymphatics requires β1- and β2-integrins on dendritic cells to engage with their counter receptors ICAM-1 and VCAM-2 on LECs ([@B84]; [@B170]; [@B80]). It has been hypothesized that the LYVE-1-hyaluronan and integrin-ICAM-1/VCAM-2 pathways may coordinate the stepwise entry of leukocytes into afferent lymphatics ([@B80]). However, this stands in contrast to the observations that lymphatic transmigration and many other inflammatory responses remain unaffected in *LYVE-1-null* mice ([@B61]; [@B108]). One possibility is that other lymphatic receptors could compensate for the loss of LYVE-1 function during leukocyte transmigration. Further studies to identify such factors and the possible underlying mechanisms are warranted.

Connexins {#S3.SS5}
---------

Connexins are a family of transmembrane proteins consisting of 21 members in human and 20 members in mouse that assemble into pore-forming hexamers called connexons. Connexons can function as hemichannels in the plasma membrane for cytosol-extracellular diffusion or dock together across adjacent cells to form complete intercellular gap junctions that mediate direct cell-cell communication ([@B66]). The role of connexin-mediated homocellular or heterocellular coupling of BECs and vascular smooth muscle cells has been well studied in blood vessels ([@B54]; [@B125]; [@B126]). In contrast, much less is known about connexins in lymphatic vessels; their *in vivo* expression pattern and function in LECs and lymphatic smooth muscle cells have only begun to be unveiled in recent years.

[@B89] showed that Connexin37, Connexin43, and Connexin47 are variably expressed in the endothelium of developing and mature collecting lymphatics. Both Connexin37 and Connexin43 are crucial for normal lymphatic development and function, as evident by the various abnormalities in lymphatic vessel patterning and valve formation, and the presence of lymphedema in *Connexin37*-, *Connexin43-* or *Connexin37*;*Connexin43-null* mice ([@B89]; [@B139], [@B140]; [@B119], [@B118]; [Table 1](#T1){ref-type="table"}). During embryogenesis, Connexin37 is required for maintaining the proper size of the jugular lymph sac, and both Connexin37 and Connexin43 critically regulate thoracic duct development. Intriguingly, Connexin43 and Connexin37 are enriched in a subset of LECs in mature lymphatic valves and have a differential distribution at the upstream and downstream sides of the valves, possibly due to unequal flow shear forces exerted on either side of the valve ([@B89]). High expression of Connexin37 in valve LECs depends on PROX1, FOXC2 and flow shear stress ([@B139], [@B140]). Consistent with their abundant expression in valve LECs, deletion of *Connexin37*, *Connexin43* or both, results in partial or complete loss of lymphatic valve formation ([@B89]; [@B139], [@B140]; [@B119], [@B118]). On the other hand, connexin47 expression is highly restricted to a very small portion of valve LECs on the upstream side of the valve, but the ablation of *Connexin47* alone does not result in lymphatic valve defects or lymphedema in mice ([@B119]; [@B114]). Interestingly, mutations in *GJA1* (Connexin43) and *GJC2* (Connexin47) have been linked to human primary and secondary lymphedema ([@B53]; [@B128]; [@B55]; [@B16]). However, Connexin43 or Connexin47 single mutant mice exhibit no lymphedema, and the lymphedema phenotype can only been seen in *Connexin37^--/--^;Connexin43^--/--^* mice and some *Connexin43^--/--^;Connexin47^--/--^* mutant mouse embryos ([@B89]; [@B139]). Furthermore, human patients with connexin mutations show no signs of the developmental lymphatic valve abnormalities observed in *Connexin47*-, *Connexin43-* or *Connexin37-null* mice ([@B53]; [@B128]; [@B55]; [@B16]). These discrepancies raise the question of how the mechanism underlying the defective lymphatic vessel and valve development in connexin mutant mice could relate to the pathogenesis of lymphedema in human patients carrying connexin mutations.

The smooth muscle cell layer of collecting lymphatics generates intrinsic spontaneous contractions that are required for propulsion of lymph. Therefore, loss of lymphatic contractile capacity due to smooth muscle cell dysfunction may be a component of lymphedema and other diseases that are characterized by deficient lymphatic transport. Connexin45, the predominant connexin isoform in lymphatic smooth muscle cells, is essential to the entrainment of lymphatic contraction waves. Connexin45 deficiency disrupts the electrical communication in the smooth muscle layer of lymphatics and largely impairs lymphatic contraction and pumping capability ([@B21]). However, these defects do not result in inhibition of lymph transport *in vivo*, unless a chronic gravitational load is imposed. This is consistent with evidence that lymph transport relies not only on smooth muscle contraction, but also on other driving forces (e.g., interstitial pressure). A partial-to-severe loss of lymphatic pumping function alone is insufficient to abolish forward movement of lymph. Nevertheless, *GJC1* (Connexin45) mutations have not been identified in human lymphedema patients ([@B156]). Thus, whether a Connexin45 deficiency in lymphatic smooth muscle cells is involved in the pathogenesis of this disease remains yet unclear.

Despite the important advances in understanding the roles of connexins in the lymphatic vasculature, many fundamental questions about lymphatic connexins remain unanswered. First and most importantly, are connexins assembled into gap junction structures in adjacent LECs and smooth muscle cells in the lymphatic wall? If yes, are they integrated with other junctional proteins? In which signaling pathways are connexins involved in those cells? Finally, elucidating the interplay between LEC and smooth muscle cell connexins in mediating cytosol-to-extracellular and cell-to-cell communications will be of particular importance in order to understand key lymphatic functions, such as lymphatic vessel growth, contraction and flow responses.

LEC Junctions in Development {#S4}
============================

In mice, the development of the lymphatic vasculature is initiated at approximately E9.5, when a population of endothelial cells in the anterior cardinal vein start expressing PROX1 and become lymphatic endothelial progenitor cells ([@B183]; [@B157]; [@B48]). The VEGF-C/VEGFR3 signaling axis subsequently drives budding of PROX1-positive cells from the cardinal vein to form primitive lymphatic structures called lymph sacs ([@B90]; [@B71]). As developmental lymphangiogenesis proceeds, new lymphatic vessels grow out centrifugally of the lymph sacs and eventually form the majority of the lymphatic vascular tree ([@B177]). Of note, recent lineage-tracing studies ([@B94]; [@B111]; [@B159]) have identified additional LEC progenitors from non-venous origins (e.g., hemogenic endothelium) in multiple organs including skin dermis, heart and mesentery that also give rise to new lymphatics. The precise cell identity of these precursors deserves further studies.

Interestingly, developing lymphatics have zippers, but not buttons. [@B193] showed that LECs in the E12.5 jugular lymph sacs and E16.5 trachea lymphatics are joined exclusively by zipper junctions. Importantly, LEC progenitors budding from the cardinal vein at E10.5−E12.5 are also connected to each other by zippers ([@B191]; [@B193]). Similar junctions are present at the tips of growing lymphatic sprouts regardless of age ([@B6]; [@B191]; [@B193]). Hence, when lymphatic budding or sprouting takes place, zipper junctions are developed to maintain close cell-cell contacts between LECs in such a manner that these cells can migrate as a cohesive unit. This is in agreement with the general requirement for tight cell-cell junctions during collective cell movement, in order to maintain tissue integrity, control cell polarity and ensure cell-cell communication ([@B79]; [@B58]). Indeed, targeted disruption of VE-cadherin in LECs starting at E10.5 prevents primitive lymphatic structures from remodeling and maturing, supporting the essential role of stable zipper junctions during lymphatic development ([@B70]). On the other hand, excessive stabilization of endothelial cell junctions in mice due to covalent fusion between VE-cadherin and α-catenin strongly suppresses embryonic lymphangiogenesis ([@B32]), suggesting that lymphatic development critically depends on the balanced adhesive strength of zipper junctions. PROX1 ([@B86]), RASIP1 ([@B106]), GATA2 ([@B109]) and miR-126 ([@B109]) have been identified as important regulators of VE-cadherin as well as other junction proteins in developing lymphatics. In conclusion, several lines of evidence support that VE-cadherin dynamics at adherens junctions of zippers are very important for lymphatic vessel development ([@B6]; [@B191], [@B190]; [@B193]; [@B70]). Whether tight junction and gap junction proteins contribute to the formation of zipper junctions and collective cell migration in developing lymphatics is currently unknown.

Buttons start to replace zippers in initial lymphatics at E16.5−E17.5 ([@B193]; [@B199]). As lymphatic capillary networks develop, buttons become more abundant from E17.5 to birth and into adulthood and eventually occupy almost 100% of junctional points in the lymphatic capillaries at postnatal day 70. Intermediates of the two junction types appear during the process of button formation ([@B193]). At the same time, junctions in the endothelium of collecting lymphatic vessels remain zippers ([@B193]; [@B199]). Taken together, the facts that (1) the appearance and disappearance of intermediate junctions coincide with a decrease in zippers and increase in buttons, and (2) all of these junction types have the same protein composition strongly suggest that zippers in developing initial lymphatics transform into buttons via intermediate forms. This process, referred to as "zipper-to-button" transformation, may involve redistribution of existing junctional structures at cell borders rather than assembly of new ones. The precise molecular mechanisms responsible for button formation during development remain largely unknown. It has been postulated that birth may induce rapid button formation in order to guarantee efficient clearance of amniotic fluid by lung lymphatics after the onset of breathing and immediate absorption of dietary fat by lacteals after initiation of feeding ([@B97]; [@B193]; [@B198]). The emergence of buttons is coincident with the establishment of a fully functional immune system, raising the question of whether developing immune cells are involved in the regulation of button formation and maturation. Previous studies have suggested that dexamethasone and the growth factor angiopoietin-2 (ANGPT2) promote button formation during development ([@B193]; [@B199]), whereas inflammation or inhibition of a few endothelial factors leads to a reversal process, "button-to-zipper" transformation ([@B193]; [@B10]; [@B198]). These findings will be discussed subsequently.

LEC Junctions in Lipid Uptake and Obesity {#S5}
=========================================

One of the main functions of lymphatic vessels of intestinal villi (lacteals) is to absorb dietary lipids, or chylomicrons, from the gut and transport them to the blood. The intestinal lymphatic system consists of lacteals, which reside at the center of intestinal villi and take up chylomicrons, and mesenteric collectors that drain chylomicrons into the thoracic duct and eventually into the venous circulation ([@B135]; [@B11]; [@B131]; [@B27]). Despite the recognized importance of lacteals as mediators of lipid uptake, the cellular mechanisms controlling chylomicron entry into lacteals have remained elusive for years. Some reports have suggested that chylomicrons are preferentially taken up by a specialized subset of cells located at the lacteal tip ([@B102]; [@B135]), while studies based on electron microscopy have suggested that chylomicrons enter through LEC junctions in lacteals or pass through lacteals by transcytosis ([@B42], [@B43]). We and others have shown that under baseline conditions, lacteals display predominately buttons ([@B10]; [@B198]), thus demonstrating features of initial lymphatics. Ultrastructural visualization of wild-type mouse intestinal villi has clearly shown that chylomicrons enter the lacteal lumen through junctional openings on the lacteal wall ([@B129]; [@B19]; [@B198]). Indeed, lipid absorption by lacteals requires the presence of button junctions. Certain endothelial signaling pathways, such as VEGF-A/VEGFR2, DLL4/Notch and ROCK signaling, critically control lipid uptake by regulating lacteal junction morphology ([@B10]; [@B198], see below). Most importantly, inducing button-to-zipper transformation by targeting the aforementioned signaling pathways, prevents lipid uptake into the bloodstream, thereby rendering mice resistant to diet-induced obesity and associated metabolic syndromes. Similarly, microbiota depletion in the small intestine has been shown to compromise lacteal maturation and maintenance and induce lacteal junction zippering, leading to impaired lipid absorption ([@B161]). Thus, gut microbiota is also essential for maintaining lacteal button junctions, and plays a crucial role in lipid uptake in the small intestine ([@B130]). As such, gut microbiota might be a suitable therapeutic target against obesity and other metabolic disorders. Collectively, these findings suggest that chylomicron uptake by lymphatics relies on lacteal button junctions, and that zippering (closing) of the lacteal junctions represents an attractive novel strategy for preventing plasma lipid uptake and obesity.

*Prox1^+/--^* mice, which present dilated and leaky mesenteric lymphatics possibly due to lymphatic cell junction defects, exhibit excessive accumulation of perimesenteric fat and adult-onset obesity ([@B72]; [@B86]; [@B50]). In line with this, *Apelin-null* mice fed with a high fat diet for 5 weeks develop a more obese phenotype, which is attributed to impaired lymphatic and blood vessel integrity and increased leakiness during lymph transport ([@B144]). Taken together, it appears that loss of junction integrity on collecting lymphatics leads to chronic lymph leakage and can trigger late-onset obesity. Thus, tightening junctions in lymphatic collectors may also be useful in order to prevent or treat adult obesity.

LEC Junctions in Inflammation-Associated Conditions {#S6}
===================================================

A number of inflammatory diseases, such as respiratory tract inflammation and inflammatory bowel disease, are accompanied by lymphangiogenesis ([@B91]). Detailed characterization of trachea lymphatics after *Mycoplasma pulmonis* infection suggests that such newly formed inflammation-induced lymphatics have predominantly zippers ([@B6]; [@B193]). This is in agreement with the idea that zippers are a general feature of all growing lymphatics under physiological and pathological conditions. Notably, buttons in existing lymphatics also transform into zippers during sustained inflammation and then gradually revert to buttons upon inflammation resolution ([@B193]), but the molecular basis of inflammation-induced LEC junction remodeling is still largely unknown. Functionally, junction zippering would make the inflamed lymphatics less permeable, thereby reducing fluid entry and clearance and aggravating tissue edema. In support of this, lymph flow is decreased during chronic inflammation ([@B78]; [@B200]; [@B31]), although increased lymph flow may take place at the onset of acute inflammation ([@B9]; [@B200]). As described previously, dendritic cells also utilize lymphatic button junctions; thus junction zippering may be detrimental for dendritic cell trafficking into lymphatics. Yet, enhancement of lymphatic trafficking of dendritic cells has been frequently described in the context of inflammation ([@B110]; [@B84]; [@B181]; [@B138]). This raises the possibility that leukocytes can migrate across zipper junctions in lymphatic vessels under inflammatory conditions, similarly to what has been described for blood vessels ([@B117]). Clearly, more research in this area is required to understand how inflammation-induced alterations in lymphatic junctions affect immune cell trafficking and resolution of tissue inflammation.

Notably, inflammation and infections have been implicated in the pathogenesis of secondary lymphedema ([@B196]). Although how exactly inflammation alters lymphatics structurally and functionally in the context of lymphedema remains to be determined, it is possible that junction zippering, along with other potential lymphatic dysfunctions such as retrograde lymph flow, underlies or contributes to localized fluid retention and tissue swelling in patients with inflammation-associated lymphedema. If this hypothesis is true, promoting button formation may improve lymphatic drainage function and reduce edema in these patients, hereby representing a novel therapeutic approach against this, notoriously difficult to treat, disease.

Molecular Regulation of LEC Junctions {#S7}
=====================================

ANGPT2 {#S7.SS1}
------

Angiopoietin-2 is a multifaceted growth factor that regulates blood and lymphatic vascular functions. In the blood vasculature, it can function as an agonist or an antagonist of ANGPT1/TIE2 pathway in different contexts ([@B92]; [@B96]). In the lymphatic endothelium, ANGPT2 promotes embryonic and postnatal lymphangiogenesis by acting primarily as an agonist of the TIE2 receptor ([@B62]; [@B36]; [@B155]). LECs express low levels of the orphan receptor TIE1 and no VE-PTP, which catalyzes the dephosphorylation of TIE2. This expression pattern is thought to contribute to the preferential role of ANGPT2 as a TIE2 agonist in lymphatics, given that ANGPT2-mediated TIE2 antagonism is largely dependent on TIE1/TIE2 interaction and VE-PTP activity ([@B154]; [@B155]). Additional information on the context-dependent roles of ANGPT2 in angiogenesis and lymphangiogenesis is reviewed in detail by [@B1].

Beyond these activities, ANGPT2 has also been identified as an essential regulator of LEC junctions in developing lymphatic vessels. Inhibition of ANGPT2 prevents transformation of junctions from zippers to buttons in initial lymphatics during late gestation ([@B199]), suggesting a key role of ANGPT2 in promoting junction maturation. Consistent with this, loss of ANGPT2 function leads to compromised drainage capacity and edema ([@B36]; [@B199]). Interestingly, ANGPT2 inhibition also concomitantly reduces VE-cadherin phosphorylation at tyrosine residue 685 in developing initial lymphatics ([@B199]), raising the possibility that ANGPT2 promotes button formation by controlling the phosphorylation state of VE-cadherin. In addition, ANGPT2 blockage or deletion also largely impairs junction integrity and valve formation in collecting lymphatics before and after birth, thereby resulting in lymph leakage and chylous ascites ([@B36]; [@B199]). In summary, ANGPT2 is required for proper patterning of both button and zipper junctions in lymphatics during development. However, the involvement of ANGPT1 and TIE2 receptor in this process has yet to be determined.

Dexamethasone {#S7.SS2}
-------------

Dexamethasone is widely used to treat inflammation by acting as an agonist of glucocorticoid receptor. Treatment with dexamethasone has been found not only to reduce VEGF-C-induced lymphangiogenesis, but also to induce the transformation of zippers into buttons in inflamed initial lymphatics ([@B192], [@B193]). This supports the idea that button formation is beneficial to inflammation resolution. Dexamethasone also promotes button formation during neonatal stages in the absence of inflammation ([@B193]; [@B199]), suggesting a direct effect of the steroid on lymphatic junction morphology. The signaling components that mediate the effects of dexamethasone on LEC junctions are not known. As glucocorticoid receptor activation in LECs occurred concomitantly with the formation of button junctions after treatment with dexamethasone ([@B193]), the junction remodeling is possibly mediated by glucocorticoid receptor signaling. Intriguingly, a number of studies have shown that dexamethasone enhances junctional integrity of BECs by stabilizing the anchorage of adherens junction and tight junction proteins to actin filaments and maintaining the levels of junctional components, thereby reducing vascular permeability under pro-inflammatory conditions ([@B136]; [@B12]; [@B142]). Taken together, these results reveal an interesting context-dependent action of dexamethasone in the regulation of LEC and BEC junctions.

VEGF-A/VEGFR2 Signaling {#S7.SS3}
-----------------------

Vascular endothelial growth factor-A is a major angiogenic growth factor. It signals by binding to its primary receptor VEGFR2 expressed on the surface of BECs and LECs. VEGF-A binding induces tyrosine phosphorylation of VEGFR2 at specific sites and triggers downstream signaling events that are critical for BEC survival, proliferation and migration during angiogenesis ([@B46]; [@B95]). VEGF-A signaling through VEGFR2 in LECs is also known to promote lymphatic growth before birth, but does not appear to have important impact on postnatal lymphangiogenesis ([@B37]; [@B38]; [@B197]). In blood endothelium, VEGF-A acts also to transiently increase vascular leak by opening cell-cell junctions ([@B152]; [@B44]). One well studied pathway that leads to VEGF-A induced BEC junction opening involves the phosphorylation of VEGFR2 tyrosine residue, Y951 (Y949 in the mouse) and the subsequent recruitment of the adaptor protein TSAD, activation of SRC and FAK, VE-cadherin phosphorylation and internalization, and ultimate adherens junction disassembly ([@B113]; [@B137]; [@B162]; [@B103]). Another pathway involves activation of the small GTPase RhoA and ROCK downstream of VEGFR2, which drives rearrangement of cortical actin into perpendicular stress fibers that bind to the VE-cadherin cytoplasmic tail and pull BEC junctions to open ([@B178]; [@B17]; [@B39]).

In addition to VEGFR2, VEGF-A also binds to VEGFR1 (or FLT1) and NRP1 ([@B76]; [@B63]). In the intestine, these two receptors are not expressed by intestinal LECs, but only BECs ([@B87]). Previous studies suggested that FLT1 has limited intrinsic tyrosine kinase activity in endothelial cells and rather acts as a decoy that prevents VEGF-A signaling through VEGFR2 ([@B77]; [@B150]). On the other hand, NRP1 is a single-pass non-tyrosine kinase transmembrane receptor that stimulates angiogenesis and tip cell formation via VEGFR2 dependent and independent mechanisms ([@B52], [@B51]; [@B63]; [@B4]). Interestingly, NRP1 is expressed in lymphatic valves and promotes valve formation together with PlexinA1, via interactions with semaphorin3A ([@B13]). We have recently reported ([@B198]) that mice with endothelial cell-specific deletions of both *Flt1* and *Nrp1* had reduced lipid absorption into plasma and were resistant to high fat diet-induced obesity. Mechanistically, endothelial deletion of *Flt1* and *Nrp1* led to enhanced VEGFR2 signaling and induced formation of zipper junctions in intestinal lacteals that inhibited chylomicron uptake. Similarly, increasing VEGFR2 signaling via VEGF-A stimulation promoted zippering of lacteal junctions. This stands in contrast to blood capillaries, where increased VEGFR2 signaling opens BEC junctions. Conversely, transient inhibition of VEGFR2 signaling in the double mutant mice could rescue button junctions and chylomicron uptake. As expected, LEC-specific deletion of *Nrp1* and *Flt1* receptors did not affect lacteal junctions or weight gain in mice on a high fat diet. Taken together, our results point to a cell non-autonomous effect on LEC junctions, mediated by NRP1 and FLT1 expressed by villus BECs. These data show that elevating VEGF-A/VEGFR2 signaling induces lacteal junction zippering, and that FLT1 and NRP1 in BECs function as VEGF-A decoys to antagonize this effect ([Figure 2](#F2){ref-type="fig"}). Developmentally, VEGF-A/VEGFR2 signaling together with VEGF-C/VEGFR3 provides prenatal LEC growth signals ([@B120]; [@B185]; [@B38]). However, postnatal lacteal LECs must switch from a growth state with zipper junctions to a functional state with button junctions to allow chylomicron uptake and efficient nutrition of the newborn mouse. This may entail VEGF-A antagonization by NRP1 and FLT1, thereby allowing lacteal junction maturation and chylomicron uptake after birth. This process is likely to be initiated by activation of the chylomicron processing proteins MTP and ApoB at birth ([@B198]), which leads to upregulation of FLT1 expression on BECs via ApoB ([@B5]).

![Regulation of endothelial cell-cell junctions by VEGF-A/VEGFR2 signaling in intestinal villi. VEGF-A bioavailability for VEGFR2 is limited due to VEGF-A binding to FLT1 and NRP1 which are only highly expressed in BECs. This results in continuous junctions in BECs and discontinuous buttons in LECs that allow for lacteal chylomicron uptake. Increased levels of VEGF-A or deletion of *Nrp1 and Flt1* in BECs leads to upregulated signaling through VEGFR2, which disrupts BEC junctions and, opposingly, leads to lacteal junction transformation from buttons to zippers. As a result, chylomicron uptake by lacteals is inhibited, rendering mice resistant to diet-induced obesity. BEC, blood endothelial cell; LEC, lymphatic endothelial cell; NRP1, neuropilin1; FLT1, Fms-related tyrosine kinase 1 (or VEGFR1).](fphys-11-00509-g002){#F2}

Collectively, these findings identify a novel role for VEGF-A/VEGFR2 signaling in controlling LEC junction remodeling and uptake in intestinal lacteals, although the molecular basis of this effect is still unclear. Interestingly, treatment of wildtype mice with the ROCK inhibitor Y27632 promoted LEC junction zippering and inhibited chylomicron uptake into lacteals ([@B198]). This raises the possibility that VEGFR2 signaling in LECs induces junction remodeling by inhibiting RhoA-ROCK signaling-mediated cytoskeletal rearrangement. Signaling through the VEGFR2 tyrosine residue Y949 is another pathway that may mediate VEGF-A-induced lacteal junction zippering. Evidently, further studies are necessary to elucidate the cell autonomous roles of VEGFR2 and downstream signaling pathways that regulate LEC junction remodeling. Finally it would be of interest to understand the opposing effects of VEGF-A on blood and lymphatic vasculature and to identify effectors that regulate the morphological status of lacteal junctions.

DLL4 {#S7.SS4}
----

Delta-like 4 is a major canonical Notch ligand expressed in vascular endothelial cells. DLL4/Notch signaling interplays with many other signaling pathways, such as VEGF-A/VEGFR2 and VEGF-C/VEGFR3 pathways, and has been shown to be essential for sprouting angiogenesis and vascular differentiation under various physiological and pathological conditions ([@B74]; [@B107]; [@B151]; [@B160]; [@B8]). DLL4 is also highly expressed in the lymphatic endothelium. Genetic inactivation of *Dll4* in LECs leads to lacteal regression accompanied by "button-to-zipper" transformation of lacteal junctions and reduced lipid uptake and transport capacity ([@B10]). This underlies, at least in part, the decreased fat accumulation and improved metabolic parameters observed in HFD-fed mice after DLL4 blockage ([@B60]). The cardioprotective peptide adrenomedullin and its signaling partners Calcrl and RAMP2 critically regulate lymphangiogenesis during development or after myocardial infarction ([@B59]; [@B82]; [@B93]; [@B174]), while Calcrl has been identified as an important upstream regulator of DLL4-Notch signaling ([@B33]). Through controlling DLL4 expression in LECs, Calcrl-adrenomedullin signaling is essential for maintenance of proper junction organization in lacteals, thereby contributing to lipid uptake and inflammation resolution ([@B33]). As *Dll4* deletion can enhance VEGFR2 signaling ([@B184]; [@B160]), it is possible that the "button-to-zipper" conversion phenotype in *Dll4-null* lacteals is a result of increased LEC VEGFR2 signaling, as discussed above. The exact crosstalk between Notch and VEGFR2 and its implications in LEC junction remodeling remain to be further addressed.

VEGF-C/VEGFR3 Signaling {#S7.SS5}
-----------------------

Vascular endothelial growth factor-C signaling through VEGFR3 is essential for lymphangiogenesis. After the first PROX1-positive LEC progenitors egress from the anterior cardinal vein in mouse embryos at ∼E10.5, VEGF-C/VEGFR3 signaling critically regulates a variety of LEC functions, such as proliferation, migration, differentiation and apoptosis, thereby contributing to prenatal and postnatal expansion and maintenance of the lymphatic vasculature ([@B149]; [@B131]). The VEGF-C coreceptor NRP2 modulates lymphatic vessel sprouting together with VEGFR3 ([@B189]). VEGFR3 signaling also contributes to blood vessel growth ([@B151]; [@B169], [@B168]; [@B197]) and restrains vascular permeability by limiting VEGF-A/VEGFR2 signaling ([@B73]). Yet little is known about the role of VEGFR3 signaling in junction dynamics in LECs. *In vitro* studies suggested that stimulation with VEGF-C or the VEGFR3 selective activator VEGF-C156S, slightly decreases transendothelial electrical resistance in cultured LEC monolayers ([@B15]). Moreover, systemic delivery of VEGF-C via adenovirus promotes colorectal tumor-associated lymphangiogenesis, while reducing VE-cadherin expression and lymphatic endothelial barrier integrity ([@B166]). However, recent studies have argued that VEGF-C signaling through VEGFR3 does not affect LEC junction organization either *in vivo* or *in vitro* ([@B198]). In addition, analysis of newly formed lymphatics following airway infection also suggests that inflammation-associated LEC junction remodeling does not require VEGFR3 signaling ([@B193]). Further studies will be required for a clear understanding of the roles of VEGFR3 signaling in LEC junction organization in developmental and disease conditions. Additionally, VEGFR3 and VEGFR2 form heterodimers in both BECs and LECs upon VEGF-A or VEGF-C stimulation ([@B41]; [@B122]), and previous studies have underlined the contribution of VEGFR2/VEGFR3 heterodimers to VEGF-C-driven tumor and corneal lymphangiogenesis and pulmonary lymphangiectasia ([@B194]; [@B45]). So far no data are available regarding the role of VEGFR2/VEGFR3 dimerization in the regulation of LEC junctions.

Conclusion {#S8}
==========

Since functionally specialized junctions in the lymphatic endothelium were described about a decade ago, their organization and critical contribution to the uptake and transport function of lymphatic vessels have been widely recognized. However, the understanding of LEC junctions is still very limited, and many questions remain unanswered. For example, the molecular dynamics of button formation and maturation during development are poorly understood. This process is most likely to involve cytoskeletal rearrangements driven by Rho small GTPases and other effectors. In fact, the exact molecular architecture of adherens junctions and tight junctions in LEC junctions is virtually unexplored. Whether gap junctions are present at buttons and zippers and how cells communicate with each other in initial and collecting lymphatic vessels are also unknown. LECs undoubtedly share similarities with BECs in the assembly and dynamics of zipper junctions; therefore many of the intracellular partners and associated signaling components of junctional proteins identified in BECs may play similar roles in LECs. However, it is also very likely that certain LEC specific factors contribute to the unique organization and regulation of buttons, given the distinct roles of VEGF-A in opening BEC junctions and zippering LEC junctions. The involvement of these regulatory mechanisms and factors in lymphatic function and pathophysiology of inflammation, obesity and lymphedema remains to be clarified. Increasing our ability to modulate LEC junctions independently of the blood-endothelial barrier will allow to develop novel strategies against diseases characterized by dysregulation of lipid metabolism, lymph circulation and immune reactions.
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ANGPT1

:   angiopoietin-1

ANGPT2

:   angiopoietin-2

Calcrl

:   calcitonin receptor-like receptor

CCL21

:   chemokine (C-C motif) ligand 21

CCR7

:   C-C chemokine receptor type 7

DLL4

:   delta-like 4

ESAM

:   endothelial-specific adhesion molecule

FAK

:   focal adhesion kinase

FLT1

:   Fms-related tyrosine kinase 1

FOXC2

:   forkhead Box C2

ICAM-1

:   intercellular adhesion molecule 1

JAM-A

:   junctional adhesion molecule-A

LYVE-1

:   lymphatic vessel endothelial receptor 1

MTP

:   microsomal triglyceride transfer protein

NRP1

:   neuropilin1

NRP2

:   neuropilin2

PECAM-1

:   platelet and endothelial cell adhesion molecule 1

PROX1

:   prospero homeobox 1

RAMP2

:   receptor activity-modifying protein 2

RASIP1

:   Ras-interacting protein 1

ROCK

:   Rho-associated kinase

TAZ

:   tafazzin

TIE1

:   TEK receptor tyrosine kinase1

TIE2

:   TEK receptor tyrosine kinase2

TNFα

:   tumor necrosis factor α

VE-cadherin

:   vascular endothelial cadherin

VCAM-2

:   vascular cell adhesion molecule 2

VEGF

:   vascular endothelial growth factor

VEGFR

:   vascular endothelial growth factor receptor

VE-PTP

:   vascular endothelial protein tyrosine phosphatase

YAP

:   yes-associated protein 1

ZO-1

:   zonula occludens-1.
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